{
    "clinical_study": {
        "@rank": "11668", 
        "arm_group": {
            "arm_group_label": "MabThera/Rituxan", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of MabThera/Rituxan plus methotrexate in\n      patients with active rheumatoid arthritis who have had an inadequate response to at least 1\n      DMARD treatment. All patients will receive MabThera (1000mg iv infusion) on days 1 and 15,\n      and methotrexate (10-25mg po) weekly. The anticipated time on study treatment is 3-12\n      months."
        }, 
        "brief_title": "A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy", 
        "completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  adult patients, 18-80 years of age;\n\n          -  rheumatoid arthritis after inadequate response to >=1 DMARD treatment;\n\n          -  active disease;\n\n          -  DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study\n             treatment.\n\n        Exclusion Criteria:\n\n          -  autoimmune disease other than rheumatoid arthritis;\n\n          -  bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within\n             24 weeks of MabThera infusion;\n\n          -  concurrent treatment with any DMARD or antiTNF-alfa;\n\n          -  intra-articular or parenteral corticosteroids within 4 weeks prior to screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02006706", 
            "org_study_id": "ML20388"
        }, 
        "intervention": [
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "1000 mg iv Days 1 and 15", 
                "intervention_name": "rituximab [MabThera/Rituxan]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "10 - 25 mg/week", 
                "intervention_name": "methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MabThera/Rituxan", 
                "description": "iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion", 
                "intervention_name": "methylprednisolone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methotrexate", 
                "Rituximab", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Methylprednisolone", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 3, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia", 
                        "zip": "11000"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Niska Banja", 
                        "country": "Serbia", 
                        "zip": "18250"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nova Sad", 
                        "country": "Serbia", 
                        "zip": "21000"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Serbia"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Serbia: Medicines and Medical Devices Agency of Serbia"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in disease activity DAS 28 score", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02006706"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "24 weeks"
        }, 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}